[{"address1": "2200 Bridge Pkwy", "address2": "Suite 102", "city": "Redwood City", "state": "CA", "zip": "94065", "country": "United States", "phone": "650 549 1400", "website": "https://www.jaspertherapeutics.com/", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.", "fullTimeEmployees": 45, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ronald A. Martell", "age": 61, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1008172, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Judith Anne Shizuru M.D., Ph.D.", "age": 66, "title": "Co-Founder & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 296300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeetinder Singh Mahal M.B.A.", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 648717, "exercisedValue": 0, "unexercisedValue": 13724}, {"maxAge": 1, "name": "Dr. Edwin Jonathan Tucker M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 433326, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Herbert C. Cross", "age": 51, "title": "CFO & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Luca  Di Noto Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Ku M.D.", "title": "Vice President of Corporate Development, Portfolio Strategy & Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Ford", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wendy  Pang M.D., Ph.D.", "title": "Senior Vice President of Research & Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Carlos", "title": "Senior Vice President of Regulatory Affairs & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 16.37, "open": 16.66, "dayLow": 15.77, "dayHigh": 16.9, "regularMarketPreviousClose": 16.37, "regularMarketOpen": 16.66, "regularMarketDayLow": 15.77, "regularMarketDayHigh": 16.9, "beta": 2.22, "forwardPE": -3.8746986, "volume": 109402, "regularMarketVolume": 109402, "averageVolume": 204264, "averageVolume10days": 258370, "averageDailyVolume10Day": 258370, "bid": 15.94, "ask": 16.34, "bidSize": 100, "askSize": 100, "marketCap": 242893216, "fiftyTwoWeekLow": 4.0, "fiftyTwoWeekHigh": 31.01, "fiftyDayAverage": 19.2368, "twoHundredDayAverage": 19.920725, "currency": "USD", "enterpriseValue": 138390224, "floatShares": 8832522, "sharesOutstanding": 15105300, "sharesShort": 1934812, "sharesShortPriorMonth": 1837769, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.12810001, "heldPercentInsiders": 0.049489997, "heldPercentInstitutions": 0.99025, "shortRatio": 11.51, "shortPercentOfFloat": 0.1297, "bookValue": 6.641, "priceToBook": 2.421322, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -62436000, "trailingEps": -60.72, "forwardEps": -4.15, "enterpriseToEbitda": -2.065, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "JSPR", "underlyingSymbol": "JSPR", "shortName": "Jasper Therapeutics, Inc.", "longName": "Jasper Therapeutics, Inc.", "firstTradeDateEpochUtc": 1578666600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d05c20fd-d0e0-395b-bf20-ba58829de0f6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 16.08, "targetHighPrice": 90.0, "targetLowPrice": 55.0, "targetMeanPrice": 71.63, "targetMedianPrice": 69.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 106819000, "totalCashPerShare": 7.072, "ebitda": -67006000, "totalDebt": 2316000, "quickRatio": 10.635, "currentRatio": 10.795, "debtToEquity": 2.309, "returnOnAssets": -0.35779, "returnOnEquity": -0.59317, "freeCashflow": -34779000, "operatingCashflow": -55876000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-07"}]